Login to Your Account


Sovaldi, so good? Merck's $3.8B for Idenix gets early HCV nucs, aims to fill data 'holes'

By Randy Osborne
Staff Writer

Tuesday, June 10, 2014
Bolstering its hepatitis C virus (HCV) position as patent skirmishes continue in the space, Merck & Co. Inc. snatched up Idenix Pharmaceuticals Inc. for $24.50 in cash per share, or about $3.85 billion, in a 300 percent-plus premium deal approved by the boards of both companies and set to close during the third quarter of this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription